Enhancement of anti-inflammatory property of aspirin in mice by a nano-emulsion preparation

International Immunopharmacology

Volumn 8, Issue 11, 2008, Pages 1533-1539

  Subramanian, Balajikarthick ^a   Kuo, Fonghsu ^a   Ada, Earl ^a   Kotyla, Tim ^a   Wilson, Thomas ^a   Yoganathan, Subbiah ^b   Nicolosi, Robert ^a  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b FORSYTH INSTITUTE   (United States)

Author keywords

Anti inflammatory; Aspirin; Croton oil; Inflammation; Nano emulsion; Nanotechnology

Indexed keywords

ACETYLSALICYLIC ACID; CROTON OIL; INTERLEUKIN 1ALPHA; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVICE; EXTERNAL EAR; INFLAMMATION; MALE; MICROEMULSION; MICROFLUIDICS; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROTON OIL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EDEMA; EMULSIONS; INFLAMMATION; INTERLEUKIN-1ALPHA; MALE; MICE; NANOSTRUCTURES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51749118891     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.06.009     Document Type: Article

References (47)

1. Awtry E.H., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
2. Amann R., and Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447 (2002) 1-9
3. Beauparlant P., and Hiscott J. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev 7 2 (1996) 175-190
4. Vane J.R., and Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104 3A (Mar 30 1998) 2S-8S discussion 21S-22S
5. Kenneth K., and Wu. Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb Res 110 5-6 (2003) 273-276
6. Kenneth R., McQuaid, and Loren L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 8 (2000) 624-638
7. Laine L., and McQuaid K. Bleeding complications related to aspirin dose. Am J Cardiol 96 (2005) 1035-1036
8. Hallas J., Dall M., Andries A., Andersen B.S., Aalykke C., Hansen J., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 7571 (2006) 726-731
9. Young R.S., Torretti D., Williams R.H., Hendriksen D., and Woods M. Reye's syndrome associated with long-term aspirin therapy. JAMA 251 6 (1984) 754-756
10. Mina Alfred A, Knipfer, John F, Park, David Y, Bair, Holly A, MSN, Howells, Greg, A., Bendick, Phillip J. Intracranial Complications of Preinjury Anticoagulation in Trauma Patients with Head Injury. J Trauma 2002; Oct 53(4): 668-672.
11. Zhang B., He X.L., Ding Y., and Du G.H. Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug. Eur J Pharmacol 530 1-2 (2006) 166-171
12. Kim S.H., Ye Y.M., Lee S.K., and Park H.S. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol 6 4 (2006) 266-270
13. Chan C., Boyce S., Brideau C., Charleson, Cromlish W., Ethier D., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290 (1999) 551-560
14. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284 10 (2000) 1247-1255
15. Rao P.N., Chen Q.H., and Knaus E.E. Synthesis and structure-activity relationship studies of 1, 3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. J Med Chem 49 5 (2006) 1668-1683
16. Ammar O.H., Ghorab M., El-ahhas S.A., and Kamel R. Design of a transdermal delivery system for aspirin as an antithrombotic drug. Int J Pharm 327 (2006) 81-88
17. Kogan A., and Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 123-126 (2006) 369-385
18. Yamaguchi M., Yasueda S., Isowaki A., Yamamoto M., Kimura M., Inada K., et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 301 1-2 (2005) 121-128
19. Tiwari S.B., and Amiji M.M. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 6 9-10 (2006) 3215-3221
20. Pinnamaneni S., Das N.G., and Das S.K. Compariosn of oil-in-water emulsions manufactured by microfluidization and homogenization. Pharmazie 58 8 (2003) 554-558
21. Janjic J.M., Srinivas, Kadayakkara D.K., and Ahrens E.T. Self delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc 130 9 (2008) 2832-2841
22. Tadros T., Izquierdo P., Esquena J., and Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 108-109 (2004) 303-318
23. Bouchemal K., Briancon S., Perrier E., and Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimization. Int J Pharm 280 1-2 (2004) 241-251
24. Kuo F., Kotyla T., Wilson T., Kifle L., Panagiotou T., Gruverman I., et al. Thomas Shea and Robert Nicolosi. A nanoemulsion of an anti oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing mice. J Exp Ther Oncol 6 2 (2007) 129-135
25. Wilmer J.L., Burleson F.G., Kayama F., Kanno J., and Luster M.I. Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin. J Invest Dermatol 102 6 (1994) 915-922
26. Towbin H., Pignat W., and Wiesenberg I. Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone. Inflamm Res 44 Suppl 2 (1995) S160-S161
27. Charles A., and Dinarello M.D. Proinflammatory cytokines. Chest 118 (2000) 503-508
28. Smiley T.S., Kaplan M.H., and Grusby M.J. Immunoglobin E production in the absence of interleukin-4-secreting CD1 dependent cells. Science 275 (1997) 977-983
29. Koyuncu H., Berkarda B., Baykut F., Soybir G., Alatli C., Gul H., et al. Preventive effect of hesperidin against inflammation in CD-1 mice skin caused by tumor promoter. Anticancer research 19 (1999) 3237-3241
30. Berger A., Monnard I., Baur M., Charbonnet C., Safonova I., and Jomard A. Epidermal anti-inflammatory properties of 5, 11, 14, 20:3: effects on mouse ear edema, PGE2 levels in cultured keratinocytes and PPAR activation. Lipids Health Dis 1 (2002) 12-17
31. Yoganathan S., Nicolosi R., Wilson T., Handelman G., Scollin P., Tao R., et al. Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 38 6 (2003) 603-607
32. Kikuchi T., Ito N., Suzuki M., Kusai A., Iseki K., and Sasaki H. Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl] phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent. Int J Pharm 299 1-2 (2005) 100-106
33. Desai A., Vyas T., and Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 97 7 (2008) 2745-2756
34. Zhao X., Liu J.P., Zhang X., and Li Y. Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int J Pharm 327 (2006) 58-64
35. Lopez A., Sims D.E., Ablett R.F., Skinner R.E., Leger R.E., Lariviere C.M., et al. Effect of emu oil on auricular inflammation induced with croton oil in mice. Am J Vet Res 60 12 (Dec 1999) 1558-1561
36. Kumar R., Chen M.H., Parwar V.S., Samuelson L.A., Kumar J., Nicolosi R., et al. Supramolecular assemblies based on co polymers of PEG 600 and functionalized aromatic diesters for drug delivery applications. J Am Chem Soc 126 (2004) 10640-10644
37. Takeda S., Terazono B., Mishima F., Nakagami H., Nishijima S., and Kaneda Y. Novel drug delivery system by surface modified magnetic nanoparticles. J Nanosci Nanotechnol. 6 9-10 (2006) 3269-3276
38. Yuan X., Li L., Rathinavelu A., Hao J., Narasimhan M., He M., et al. SiRNA drug delivery by biodegradable polymeric nanoparticles. J Nanosci Nanotechnol. 6 9-10 (2006) 2821-2828
39. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28 5 (2007) 869-876
40. Thanos C.G. Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly (fumaric-co-sebacic) anhydride. Pharm Res 20 7 (2003) 1093-1100
41. Vila A., Sanchez A., Evora C., Soriano I., Mc Callion O., and Alonso M.L. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 292 1-2 (2005) 43-52
42. Wu H., Ramachandran C., Weiner N.D., and Roessler B.J. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm 220 1-2 (2001) 63-75
43. Sarker D.K. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2 4 (2005) 297-310
44. Shafiq S., Shakeel F., Talegaonkar S., Farhan Ahmad J., Khar R.K., and Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm BioPharm 66 (2007) 227-243
45. Khandavilli S., and Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol 127 (2007) 154-162
46. Ikonomidis I., Andreotti F., Economou E., Stefanadis C., Toutouzas P., and Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100 8 (1999) 793-798
47. Tiran A., Gruber H.J., Graier W.F., Wagner A.H., Vaneeuwen E.B., and Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol. 22 7 (2002) 1075-1080